Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Patients can present as heterozygotes with only one gene encoding for an abnormal enzyme, or as a homozygote with both genes encoding for the defective enzyme
Purely from a value perspective, we should be even more underallocating here, but I feel that we might be betting on Novo Nordisk a bit too much
Metabolic Syndrome Resolution Post-hoc analysis of SURPASS trials demonstrated substantial reductions in metabolic syndrome prevalence: Significant improvements in multiple cardiovascular risk factors simultaneously Reductions in blood pressure, improved lipid profiles, and decreased waist circumference Resolution of metabolic syndrome criteria in a substantial proportion of participants Potential long-term cardiovascular benefits from comprehensive metabolic improvements Cardiovascular and Metabolic Comorbidities Heart Failure with Preserved Ejection Fraction (HFpEF) The SUMMIT phase 3 trial evaluated GLP2 in adults with HFpEF and obesity: Statistically significant reduction in heart failure outcomes (composite endpoint) Improvements in heart failure symptoms and physical limitations measured by Kansas City Cardiomyopathy Questionnaire Enhanced exercise capacity as measured by 6-Minute Walk Test Distance Reduction in high-sensitivity C-reactive protein (inflammation marker) These findings established GLP2 as the first incretin therapy to demonstrate benefits on heart failure outcomes in this population
Only 6% (n=30) were vaccinated against HBV, 92% (n=453) were not vaccinated, and 2.4% (n=12) reported not knowing vaccination status
